Evaluating antibiotic effectiveness in patients with infections
Official title: Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment and the Potential Role of Therapeutic Drug Monitoring in UK Infection Management
Run by Imperial College London · NCT06427317 · Data updated 2026-11-12
This study is testing how well beta-lactam antibiotics work for patients with infections by checking if they get the right amount of the medicine in their system to help them recover.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 323 (estimated) |
| Sponsor | Imperial College London Academic / other |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | March 19, 2024 |
| Main results expected | March 19, 2027 |
| Study ends | March 19, 2027 |
| Registry record updated | May 23, 2024 |
| Trial ID | NCT06427317 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 who are being treated for infections and have received beta-lactam antibiotics within the last 48 hours.
✕Probably not a fit
Patients under 18, those with severe blood disorders, or those receiving palliative care may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to determine how many patients at Imperial College Healthcare NHS Trust receiving beta-lactam antibiotics achieve the necessary drug concentration targets for effective treatment. By analyzing routinely collected clinical data and drug concentration samples, the study seeks to understand the relationship between clinical variables and treatment outcomes. It also aims to identify gaps in current dosing practices and prioritize areas for further research on drug optimization. Participants will be monitored during their infection management, providing valuable insights into antimicrobial effectiveness.
Why it matters
Potential benefit: If successful, this study could lead to improved antibiotic dosing strategies, enhancing treatment outcomes and reducing the risk of antimicrobial resistance.
How similar studies have gone: While the approach of optimizing antibiotic dosing is well-recognized, this specific observational study may provide novel insights into real-world dosing effectiveness.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 18 years of age or above. * Under follow-up for management of infection at Imperial College NHS Trust * Received a beta-lactam antibiotic within the last 48 hours (or are planned to start imminently). * Provides informed written consent see below, or lacks capacity to provide consent because of one of the following conditions (and declaration provided by personal consultee): * Delirium which may be caused or exacerbated by having an infection. * Suspected/confirmed central nervous system infection. * Critical illness requiring sedation and/or intubation and ventilation which is caused by or exacerbated by having an infection. Exclusion Criteria: * Less than 18 years of age * Severe anaemia (Hb \< 70g/l) * Platelets \< 50x10\^9/l, INR \>1.5 or other known blood clotting impairment * Patient with terminal diagnosis receiving palliative care input who may experience distress if approached for this study. * Enrolled in a clinical trial which stipulates exclusion from other studies including observational studies. * Patients with restricted liberty, prisoners or under legal protection.
Where it's running
-
Imperial College Healthcare NHS Trust
London, United Kingdom Recruiting
Study contacts
- Principal investigator: Alison Holmes, MD — Imperial College London
- Study coordinator: Suzy Williams
- Email: suzanne.williams@imperial.ac.uk
- Phone: +44 (0) 20 3313 2732
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Levetiracetam Dosing in Critically Ill on CRRT
This study tests how levetiracetam behaves in the bodies of adults on continuous renal replacement therapy to help figure out the best dosing.
-
Trigonelline Monohydrate for NAD+ Metabolism in Healthy Adults
A small study in healthy adults tests whether taking trigonelline monohydrate by mouth for 4 weeks can change NAD+ levels and how the body handles the supplement, compared with NMN and placebo.
-
Cetuximab bioequivalence test in healthy men
This study tests whether a cetuximab injection is bioequivalent to Erbitux in healthy men to see if they behave the same in the body.
-
GenSci142 as a vaginal treatment for bacterial vaginosis
This study tests whether GenSci142 given as vaginal doses is safe and may help BV patients aged 18–50 compared with clindamycin cream.
-
UGT1A1 gene and side effects from certain antibody-drug treatments for advanced breast cancer
This project will test whether common UGT1A1 gene variants explain who gets worse side effects from antibody-drug conjugates (sacituzumab-govitecan, trastuzumab-deruxtecan, or datopotamab-deruxtecan) in adults with advanced breast cancer.
-
Telenursing to detect and manage side effects from CDK4/6 inhibitors in breast cancer
This project tests whether scheduled phone or video contacts from trained nurses, added to usual care, help people with breast cancer taking CDK4/6 inhibitors notice and manage side effects earlier and stay on treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.